Drug · DIN 02519038
BLEXTEN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 10, 2022; first marketed February 10, 2022.
- Drug Identification Number (DIN)
- 02519038
- Company (DIN owner)
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet (Orally-Disintegrating)
- Route
- Oral
- Therapeutic class (ATC)
- Bilastine R06AX29
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BILASTINE | 10 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 11, 2021: NOC 26399Supplement to a New Drug Submission (SNDS) · Expand pediatric indication, addition of new dosage forms and to update the Product Monograph to the 2020 format.
Other DINs named BLEXTEN
- DIN 02454130 · Marketed
- DIN 02519011 · Marketed
- DIN 02561514 · Approved